ESTRELLA IMMUNOPHARMA, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $17.14 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $76.48K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$59.33K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $162.80K, a 1173.96% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$35.15K, a 161.50% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $36.65K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was -$449.96K, a 467.03% decline from fiscal 2023.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $122.59K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $76.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $17.14K 10-Q · filed 2026-08-13 | $179.94K derived: sum of 3 quarters · filed 2026-08-13 | $144.79K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$59.33K 10-Q · filed 2026-05-18 | $103.47K derived: sum of 2 quarters · filed 2026-05-18 | $68.31K derived: sum of 3 quarters · filed 2026-05-18 | $61.24K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $162.80K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $127.65K derived: sum of 2 quarters · filed 2026-03-18 | $120.57K derived: sum of 3 quarters · filed 2026-08-13 | $36.65K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$35.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$42.23K derived: sum of 2 quarters · filed 2026-08-13 | -$126.14K 10-Q · filed 2025-11-12 | -$113.37K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$7.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$90.99K 10-Q · filed 2026-08-13 | -$78.21K derived: sum of 3 quarters · filed 2026-08-13 | -$21.06K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$83.92K 10-Q · filed 2026-05-18 | -$71.14K derived: sum of 2 quarters · filed 2026-05-18 | -$13.98K derived: sum of 3 quarters · filed 2026-05-18 | $28.43K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $12.78K derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-18 | $69.94K 10-K · filed 2026-03-18 | $112.35K derived: sum of 3 quarters · filed 2026-03-18 | -$68.82K derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-09-30 | $57.16K 10-Q · filed 2024-11-14 | $99.57K derived: sum of 2 quarters · filed 2025-08-12 | -$81.60K 10-Q · filed 2025-11-12 | -$787.57K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-06-30 | $42.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$138.76K 10-Q · filed 2025-08-12 | -$844.72K derived: sum of 3 quarters · filed 2025-08-12 | -$449.96K 10-KT · filed 2025-03-25 |
| 2024-03-31 | -$181.17K 10-Q · filed 2025-05-14 | -$887.13K derived: sum of 2 quarters · filed 2025-05-14 | -$492.37K 10-Q · filed 2024-05-15 | -$425.59K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$705.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | -$311.20K 10-Q · filed 2024-02-14 | -$244.42K derived: sum of 3 quarters · filed 2024-11-14 | -$206.76K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-09-30 | $394.77K 10-Q · filed 2024-11-14 | $461.55K derived: sum of 2 quarters · filed 2024-11-14 | $499.21K derived: sum of 3 quarters · filed 2024-11-14 | $451.31K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $66.78K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-27 | $104.44K derived: sum of 2 quarters · filed 2024-09-27 | $56.54K derived: sum of 3 quarters · filed 2024-09-27 | $122.59K 10-K · filed 2024-09-27 |
| 2023-03-31 | $37.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | -$10.24K derived: sum of 2 quarters · filed 2024-05-15 | $55.81K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | -$47.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $18.15K 10-Q · filed 2024-02-14 | ||
| 2022-09-30 | $66.05K 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |